"We describe the development and clinical translation of a targeted
polymeric nanoparticle (TNP) containing the chemotherapeutic docetaxel (DTXL)
for the treatment of patients with solid tumors. DTXL-TNP is targeted to
prostate-specific membrane antigen, a clinically validated tumor antigen
expressed on prostate cancer cells and on the neovasculature of most
nonprostate solid tumors. DTXL-TNP was developed from a combinatorial library
of more than 100 TNP formulations varying with respect to particle size,
targeting ligand density, surface hydrophilicity, drug loading, and drug
release properties."
I am impressed – we have
all important key words here:
-
polymeric
nanoparticle
-
targeted,
targeting ligand density
-
a
clinically validated tumor antigen
-
combinatorial
library
Usually
it is necessary to have just one of these keywords to brag that you develop
very promising drug, therefore in this case we have at least blockbuster
candidate (if not a magic bullet!) I do believe that the authors have done a
lot of hard work. Well, it would be impolite to say that the drug will not be
successful in coming clinical trials; therefore I am just keeping silence…
No comments:
Post a Comment